SAWAI GROUP HOLDINGS Co., Ltd. (4887) Stock Price

Sawai Group Holdings holds equity stakes in domestic and international subsidiaries engaged in the manufacture and sale of pharmaceuticals. The company manages the business activities of these subsidiaries and provides management support and guidance. Its primary business is the manufacture and sale of prescription pharmaceuticals and over-the-counter drugs.

The company operates a single business segment focused on the manufacture and sale of pharmaceuticals. Sawai Group Holdings has classified its U.S. operations as discontinued operations and unified its reporting segment under "Manufacture and Sale of Pharmaceuticals."

Sawai Pharmaceutical manufactures pharmaceuticals and sells them directly to domestic sales companies, wholesalers, other pharmaceutical manufacturers, and medical institutions. Medisa Shinyaku engages in the sale of prescription pharmaceuticals and conducts product transactions with Sawai Pharmaceutical and other manufacturers.

Kaken Seiyaku manufactures and sells prescription pharmaceuticals and purchases products from Medisa Shinyaku. Sawai Pharmaceutical purchases key raw materials from Kaken Seiyaku. Trustpharmatech manufactures and sells prescription pharmaceuticals and is contracted by Sawai Pharmaceutical for research and development and manufacturing services.

Sawai Group Holdings aims to become a trusted company and has established "Sawai Group Vision 2030." To achieve this vision, the company has formulated a three-year medium-term management plan called "Beyond 2027," with fiscal year 2026 as the final year. This plan prioritizes enhancing reliability and developing talent to support sustainable growth.

Under its long-term vision "Sawai Group Vision 2030," Sawai Group aims to create a society where more people have access to healthcare services in their daily lives. The company seeks to contribute to people's health by providing science-based products and services tailored to individual needs. Financial targets include revenue of 310 billion yen and ROE of 13% or higher.

The medium-term management plan "Beyond 2027" focuses on steady growth in the generic drug market, developing talent to support sustainable growth, sustainability initiatives, and improving capital efficiency. Through these efforts, the company aims to establish itself as a trusted enterprise and pursue further growth.

Sawai Group Holdings pursues a shareholder return policy of stable and continuous dividends and actively executes share buybacks to improve capital efficiency. Quantitative targets are set at revenue of 220 billion yen and ROE of 10% or higher.

As a leading company in the generic drug industry, Sawai Group aims to rapidly develop and launch new generic drugs while maintaining top-tier standards in quality, stable supply, and information provision. Through these efforts, the company seeks to enhance brand value and compete effectively in the market.

Sawai Group Holdings prioritizes improving reliability, maintaining and securing stable supply, developing and launching high-value-added generic drugs, enhancing information provision, strengthening marketing functions, reinforcing corporate structure and management, and building and strengthening new business foundations. Through these initiatives, the company aims to achieve sustainable growth.